Peptide Particle Testing in 2026: Why a Clear Solution May Still Contain Subvisible Particles
A visually clear research sample is not necessarily particle-free. Learn how laboratories detect, count and investigate particles that ordinary visual inspection and HPLC purity reports may miss.
Research insight: Particle analysis answers a different question from peptide identity, chemical purity and endotoxin testing. These measurements are complementary—not interchangeable.
What are subvisible particles in peptide research?
Subvisible particles are small suspended objects that generally cannot be reliably detected with the unaided eye. They may include peptide aggregates, precipitated material, fragments shed by a container closure, fibres or other extraneous debris. A solution can look transparent while still containing measurable particles. Particle size, optical contrast and sample background all affect detectability.
Importantly, a particle is not automatically a chemical impurity. A particle formed from the peptide itself is different from a glass fragment or a fibre, and different methods may be needed to establish its origin.
Why an HPLC purity result cannot settle the question
Reversed-phase HPLC typically separates soluble chemical species under defined chromatographic conditions. Its reported peak-area percentage describes the detected chromatographic signal, not a direct count of suspended particles in the original sample. Sample preparation, dilution, filtration or dissolution may alter particulate material before analysis. Therefore, a high HPLC purity percentage does not establish that a solution is free of subvisible particles.
For a complementary discussion, read our HPLC method robustness guide and peptide aggregation research article.
How laboratories measure subvisible particles
1. Light obscuration
A liquid passes through an illuminated measurement zone. As particles interrupt the light beam, the instrument estimates their size and number. Light obscuration is an established approach in pharmacopoeial particulate testing. It is useful for counting particles within its validated measurement range, but optical properties, bubbles and sample characteristics can influence results. It generally does not reveal particle composition.
2. Membrane microscopy
Particles retained on a membrane can be examined microscopically. This can support visual characterisation, although transparent or proteinaceous material may be difficult to distinguish from the background. Sample preparation can itself affect recovery and morphology.
3. Flow imaging microscopy
Flow imaging captures pictures of individual particles as they pass through a flow cell. Images can add shape and transparency information, potentially helping researchers distinguish some particle populations. However, image classification is not definitive chemical identification, and results may differ from light obscuration because the methods have different detection responses.
4. Orthogonal identification
When particle identity matters, laboratories may combine microscopy with spectroscopic or other analytical approaches. For example, a suspected fibre, elastomer fragment or peptide-rich aggregate may require additional investigation. No single counting technique proves every particle’s origin.
What USP chapters 787, 788 and 790 actually cover
USP <788> addresses particulate matter in injections, while USP <787> specifically addresses subvisible particulate matter in therapeutic protein injections. USP <790> addresses visible particulates in injections, and USP <1790> discusses visual inspection. These are pharmaceutical contexts—not automatic specifications for nonclinical research peptide materials. The correct applicability depends on the product type, intended use and governing standard.
In its December 2021 draft guidance, the US FDA emphasised a broader risk-based approach to visible particulate control. The draft does not establish requirements for research-use-only peptides and explicitly does not cover subvisible particulate testing. Researchers should not cite it as a finalised subvisible-particle standard.
Why different methods can report different particle counts
Particle counting is method-dependent. A highly transparent particle may be less detectable by light obscuration than by an imaging system. Conversely, imaging methods have their own resolution limits and image-processing thresholds. A 2008 comparative study of protein-containing samples found that micro-flow imaging could report more particles than light obscuration under the studied conditions, even when measurements of standard particles were similar. This does not mean one method is universally superior; it shows why the measurement principle and validation matter.
What a useful particle-testing report should include
- Sample identification: batch, matrix, preparation history and time between preparation and measurement.
- Method: instrument, technique, validated size range and sample volume.
- Results: counts by defined size thresholds and appropriate units, with replicate information where applicable.
- Controls: background, blank, cleanliness and bubble-management checks.
- Interpretation: limitations, deviations and any follow-up particle-identification work.
A certificate of analysis that lists only HPLC purity and molecular mass should not be interpreted as evidence that particulate testing was performed. Conversely, a particle count does not by itself establish peptide sequence, chemical purity, sterility or endotoxin status. Explore our endotoxin and sterility distinctions for more on separate quality attributes.
Research example: clear appearance versus measured particles
Consider two hypothetical research solutions that both look clear. A laboratory might observe different particle counts because one contains more small aggregates or container-derived material. This is an illustrative scenario, not measured data for any 24hour Peptides product. The observation would prompt a method-controlled investigation—not an automatic conclusion that one sample is chemically less pure.
Key takeaway for laboratory researchers
Visual clarity, HPLC purity, mass confirmation and particulate analysis describe different properties. Good laboratory interpretation depends on asking the right question, choosing a suitable method and documenting its limitations. For wider context on peptide identity, storage, testing and research practice, see our Research Peptides UK Complete Guide.
Scientific references
- United States Pharmacopeia. USP <790> Visible Particulates in Injections.
- United States Pharmacopeia. USP <1790> Visual Inspection of Injections.
- US Food and Drug Administration (December 2021). Inspection of Injectable Products for Visible Particulates — Draft Guidance.
- Sharma DK et al. Quantitation of protein particles in parenteral solutions using micro-flow imaging. Journal of Pharmaceutical Sciences (2008).
- Overlooking Subvisible Particles in Therapeutic Protein Products: Gaps that may Compromise Product Quality. Peer-reviewed review article.
This article is provided solely for scientific and educational discussion of laboratory analytical methods. 24hour Peptides products are intended for in-vitro laboratory research only. They are not medicines, are not approved for human or veterinary use, and are not intended for administration, diagnosis or treatment. Pharmaceutical standards discussed here are contextual references and do not imply that any research product meets injectable-drug specifications.






